Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial
A personalized cancer vaccine triggered immune responses in most patients and helped one person with aggressive brain cancer survive four years.
The GT-20 Phase 1 trial tested GNOS-PV01, a DNA-based personalized neoantigen vaccine encoding up to 40 tumor-specific antigens per patient, as adjuvant treatment for MGMT unmethylated glioblastoma (the worst-prognosis subtype). The vaccine was safe, immunogenic in 8/9 patients, and met pre-specified clinical endpoints with a 4-year long-term survivor, supporting GNOS-PV01 as a component of an emerging glioblastoma immunotherapy strategy.
What the study was
- Study design
- Phase 1 single-arm open-label clinical trial (GT-20)
- Population
- Adults with MGMT unmethylated glioblastoma following surgical resection and radiation
- Sample size
- 9
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nature Cancer
Why it surfaced
First Phase 1 trial of DNA-based personalized multi-neoantigen vaccine (up to 40 antigens) for MGMT unmethylated GBM — the highest-risk glioblastoma subtype with median OS ~12-18 months on standard care. Met pre-specified endpoints; 4-year survivor observed; published in Nature Cancer. Small n=9 but Phase 1 with rare disease context. Nat Cancer publication elevates confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.